213 related articles for article (PubMed ID: 28822237)
1. Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphoma.
Kühnl A; Cunningham D; Chau I
Cancer Treat Rev; 2017 Sep; 59():132-137. PubMed ID: 28822237
[TBL] [Abstract][Full Text] [Related]
2. Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.
Bohers E; Mareschal S; Bertrand P; Viailly PJ; Dubois S; Maingonnat C; Ruminy P; Tilly H; Jardin F
Leuk Lymphoma; 2015 May; 56(5):1213-22. PubMed ID: 25130477
[TBL] [Abstract][Full Text] [Related]
3. Non-Hodgkin's lymphoma: the old and the new.
Cabanillas F
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S87-90. PubMed ID: 22035756
[TBL] [Abstract][Full Text] [Related]
4. Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers.
El Hussein S; Shaw KRM; Vega F
Mod Pathol; 2020 Dec; 33(12):2422-2436. PubMed ID: 32620919
[TBL] [Abstract][Full Text] [Related]
5. The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies.
Dubois S; Jardin F
Expert Rev Hematol; 2016 Mar; 9(3):255-69. PubMed ID: 26652775
[TBL] [Abstract][Full Text] [Related]
6. Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment.
Crombie JL; Armand P
Hematol Oncol Clin North Am; 2019 Aug; 33(4):575-585. PubMed ID: 31229155
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL).
Isshiki Y; Melnick A
Curr Cancer Drug Targets; 2021; 21(4):274-282. PubMed ID: 33413063
[TBL] [Abstract][Full Text] [Related]
8. Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP.
Cerchietti L; Leonard JP
Hematology Am Soc Hematol Educ Program; 2013; 2013():591-5. PubMed ID: 24319236
[TBL] [Abstract][Full Text] [Related]
9. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
10. The epigenetic basis of diffuse large B-cell lymphoma.
Jiang Y; Melnick A
Semin Hematol; 2015 Apr; 52(2):86-96. PubMed ID: 25805588
[TBL] [Abstract][Full Text] [Related]
11. Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature.
de Jonge AV; Roosma TJ; Houtenbos I; Vasmel WL; van de Hem K; de Boer JP; van Maanen T; Lindauer-van der Werf G; Beeker A; Timmers GJ; Schaar CG; Soesan M; Poddighe PJ; de Jong D; Chamuleau ME
Eur J Cancer; 2016 Mar; 55():140-6. PubMed ID: 26820684
[TBL] [Abstract][Full Text] [Related]
12. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
[TBL] [Abstract][Full Text] [Related]
13. Evidence-based review of genomic aberrations in diffuse large B cell lymphoma, not otherwise specified (DLBCL, NOS): Report from the cancer genomics consortium lymphoma working group.
Yenamandra AK; Smith RB; Senaratne TN; Kang SL; Fink JM; Corboy G; Hodge CA; Lu X; Mathew S; Crocker S; Fang M
Cancer Genet; 2022 Nov; 268-269():1-21. PubMed ID: 35970109
[TBL] [Abstract][Full Text] [Related]
14. Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma.
Ennishi D; Hsi ED; Steidl C; Scott DW
Cancer Discov; 2020 Sep; 10(9):1267-1281. PubMed ID: 32616477
[TBL] [Abstract][Full Text] [Related]
15. Precision medicine in diffuse large B-cell lymphoma: Hype or hope?
Prasad V
Eur J Cancer; 2016 Nov; 68():22-26. PubMed ID: 27697586
[No Abstract] [Full Text] [Related]
16. All roads lead to targeted diffuse large B-cell lymphoma approaches.
Xu PP; Huo YJ; Zhao WL
Cancer Cell; 2022 Feb; 40(2):131-133. PubMed ID: 35167823
[TBL] [Abstract][Full Text] [Related]
17. Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles.
Cillessen SA; Meijer CJ; Notoya M; Ossenkoppele GJ; Oudejans JJ
J Pathol; 2010 Apr; 220(5):509-20. PubMed ID: 20087881
[TBL] [Abstract][Full Text] [Related]
18. Diffuse large B-cell lymphoma-treatment approaches in the molecular era.
Roschewski M; Staudt LM; Wilson WH
Nat Rev Clin Oncol; 2014 Jan; 11(1):12-23. PubMed ID: 24217204
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic targeting and personalized approaches for AML.
Roboz GJ
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):44-51. PubMed ID: 25696833
[TBL] [Abstract][Full Text] [Related]
20. Next-generation prognostic assessment for diffuse large B-cell lymphoma.
Staton AD; Koff JL; Chen Q; Ayer T; Flowers CR
Future Oncol; 2015; 11(17):2443-57. PubMed ID: 26289217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
